Skip to content

Multiple Sclerosis Health Center

Select An Article

Tysabri Therapy for Multiple Sclerosis

Font Size

Tysabri is approved as single therapy for the treatment of people with relapsing forms of multiple sclerosis (MS) to reduce the frequency of flare-ups and delay progression of physical disability.

After the FDA initially approved Tysabri, the drug's manufacturer took the drug off the U.S. market due to reports of a rare, but serious brain infection called PML (progressive multifocal leukoencephalopathy). But the drug returned to the market after the drugmaker included a risk-minimization program with mandatory patient registration and periodic follow-up to identify any possible cases of PML as soon as possible.

Recommended Related to Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

People with secondary progressive multiple sclerosis (SPMS) start out with another type of MS -- relapsing-remitting multiple sclerosis. If you've been diagnosed with secondary progressive MS you may have had relapsing-remitting MS for a decade or more. That's when you may begin to experience a shift in your disease. The changes are often difficult to recognize. But you may notice that relapses may not seem to fully go away. Most people with relapsing-remitting MS -- about 80% -- eventually develop...

Read the Secondary Progressive Multiple Sclerosis article > >

The risk for PML increases with the number of doses received. Data that's been collected by the FDA indicates the risk is 0.3 per 1,000 patients treated for up to 24 months, 1.5 per 1,000 patients treated for 25-26 months, and 0.9 per 1,000 patients treated for 37-48 months.

Risk also is higher among patients treated with immune-suppressing therapy before using Tysabri. Because of this risk, Tysabri is usually recommended for patients who cannot tolerate or have not responded to other MS treatments.

Tysabri is unique among MS drugs in that it works by binding to a protein found on the surface of immune cells (white blood cells), which are believed to play a role in the damaging effects of MS. Tysabri, a monoclonal antibody, curbs the ability of white blood cells to enter the brain and spinal cord.

Who Should Receive Tysabri for Multiple Sclerosis

Tysabri can be prescribed to treat patients who have relapsing forms of multiple sclerosis. The drug reduces the frequency of MS attacks and delays worsening of physical disability.

How Is Tysabri Given for Multiple Sclerosis?

Tysabri is given to those with multiple sclerosis intravenously (through a vein) over the course of an hour every four weeks in a doctor's office.

What Are the Side Effects of Tysabri?

The most common side effects are:

It is important that patients are observed for one hour after each infusion in case an allergic reaction develops. Symptoms of allergic reactions include hives, itching, breathing problems, chest pain, nausea, flushing, dizziness, and rash.

Besides PML and allergic reactions, other serious side effects include liver damage and serious infections.

As is the case with all medications, it is important to weigh the risks and benefits carefully. Talk to your doctor to determine if this treatment is right for you.

WebMD Medical Reference

Reviewed by Neil Lava, MD on February 22, 2015
Next Article:

Today on WebMD

nerve damage
Learn how this disease affects the nervous system.
woman applying lotion
Ideas on how to boost your mood and self-esteem.
 
woman pondering
Get personalized treatment options.
man with hand over eye
Be on the lookout for these symptoms.
 
brain scan
ARTICLE
worried woman
ARTICLE
 
neural fiber
ARTICLE
white blood cells
VIDEO
 
sunlight in hands
ARTICLE
illustration of human spine
ARTICLE
 
muscle spasm
ARTICLE
green eyed woman with glasses
ARTICLE